FLAG 347
Alternative Names: FLAG-347Latest Information Update: 28 Nov 2022
At a glance
- Originator Duquesne University
- Developer FLAG Therapeutics
- Class Amines; Antineoplastics; Glutamates; Pyrimidines; Pyrroles; Small molecules; Thiophenes
- Mechanism of Action Phosphoribosylglycinamide formyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA
- 26 Apr 2021 FLAG Therapeutics has multiple patents pending for purine synthesis inhibitors (FLAG Therapeutics pipeline, April 2021)
- 26 Apr 2021 FLAG Therapeutics has multiple patents granted for purine synthesis inhibitors (FLAG Therapeutics pipeline, April 2021)